Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$250.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Canadian Regulator Approves Thrombogenics NV's Eye Drug-Reuters


Saturday, 17 Aug 2013 09:11am EDT 

Reuters reported that Belgian biotech firm Thrombogenics NV said Canadian regulator Health Canada had approved its eye drug Jetrea, the first approval the drug has received outside of the United States and Europe. 

Company Quote

8.509
-0.164 -1.89%
11 Jul 2014